Results 81 to 90 of about 76,424 (294)

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. [PDF]

, 2017
ObjectiveParkinson's disease psychosis (PDP) is a frequent complication of idiopathic Parkinson's disease (iPD) with significant impact on quality of life and association with poorer outcomes.
Bizzarri, Cummings, Fernandez, Fernandez, Fénelon, Gama, Goldman, Hack, Hubbard, Kiferle, Lertxundi, McFarland, Meltzer, Meral, Mesquita, Mocci, Munhoz, Noel, Pagonabarraga, Prohorov, Rabey, Reichmann, Rolland, Seppi, Shotbolt, Starkstein, Thomas, Vanover, Weintraub, Zhu   +29 more
core   +2 more sources

Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches.
Marcela A. Montiel, Alessandro Magliozzi, Wei Kang Lim, Carolina Gorodetsky, George M. Ibrahim, Alfonso Fasano   +5 more
wiley   +1 more source

The potential influence of estrogen-containing oral contraception on clozapine metabolism in a patient with known pharmacogenomic status [PDF]

Mental Health Clinician
Clozapine is primarily metabolized via cytochrome P450(CYP)1A2 and to a lesser extent CYP3A4, CYP2C19, and CYP2D6. Metabolic inhibitors of clozapine, such as fluvoxamine and ciprofloxacin, are important to recognize to avoid adverse drug events. Estrogen-
Alyssa K. Kuhn, Meina L. Determan, Jessica A. Wright, PharmD, Eric Matey, Jonathan G. Leung   +4 more
doaj   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Loxapine and Cyproheptadine Combined Limit Clozapine Rebound Psychosis and May Also Predict Clozapine Response

Case Reports in Psychiatry, 2016
Clozapine has been consistently shown to be superior to other antipsychotics in the treatment of psychosis. However, clozapine usage has been limited due to required routine blood monitoring and the potential for life threatening side effects.
Lila Aboueid, Richard H. McCarthy
doaj   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Automated identification of Fos expression [PDF]

, 2001
The concentration of Fos, a protein encoded by the immediate-early gene c-fos, provides a measure of synaptic activity that may not parallel the electrical activity of neurons.
Cherkerzian, S., Cohen, B.M., Ennulat, D.J., Evans, M.L., Froimowitz, M.P., Lange, N., Ma, J., Young, D.   +7 more
core   +1 more source

C‐Reactive Protein and Neutrophil‐To‐Lymphocyte Ratio: Can They Be Used Interchangeably in Tracking Clozapine‐Related Inflammation?

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT Background Clozapine initiation often triggers inflammatory responses that can alter metabolism via Cytochrome P450 1A2 (CYP1A2) suppression. Although C‐reactive protein (CRP) is the recommended marker, it may be unavailable in community settings.
Nicoline Bihelek, Chad A. Bousman, William G. Honer, Reza Rafizadeh   +3 more
wiley   +1 more source

Retrospective evaluation of sociodemographic and clinical characteristics of patients with schizophrenia receiving clozapine monotherapy and clozapine combined with different antipsychotics

European Psychiatry
Introduction Schizophrenia is a chronic mental disorder and clozapine is an atypical antipsychotic that can be used in treatment-resistant schizophrenia patients.
E. Yıldız, S. N. İspir, H. R. Demirel, S. Odabaş Ünal, M. Aydın   +4 more
doaj   +1 more source

Factors associated with costs of hospitalization of severely mentally Ill patients [PDF]

, 2016
Background: Efforts to contain costs associated with general medical care include particular efforts for psychiatric disorders. Hospitalization represents the largest component of costs for psychiatric care and there is growing interest in balancing ...
Baldessarini, RossJ, Centorrino, Franca, Curto, Martina, Girardi, Paolo, Masters, Grace A   +4 more
core   +1 more source